Ve­rastem taps board di­rec­tor and Eli Lil­ly vet Bri­an Stug­lik to right the com­mer­cial boat

When Ve­rastem part­ed ways with CEO Robert For­rester days ago, the board in­di­cat­ed that they would be look­ing for a suc­ces­sor with the com­mer­cial chops to bright­en up the fu­ture of its PI3K drug du­velis­ib.

Turns out they had a can­di­date right among them.

Bri­an Stug­lik — a di­rec­tor of two years — has now been in­stalled at the helm. The Eli Lil­ly vet be­gan tak­ing a strate­gic over­sight and ad­vi­so­ry role to Ve­rastem’s com­mer­cial group in May, the com­pa­ny added, in ad­di­tion to chair­ing the com­pen­sa­tion com­mit­tee.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER